Meeting
2023 ASCO Gastrointestinal Cancers Symposium
The optimal extent of lymph node dissection for gastric cancer with para-aortic lymph node metastases.
Authors
Takeyuki Wada
National Cancer Center Hospital, Tokyo, Japan;
Takeyuki Wada , Takaki Yoshikawa , Kenichi Ishizu , Tsutomu Hayashi , Yukinori Yamagata
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 413)
DOI
10.1200/JCO.2023.41.4_suppl.413
Abstract #
413
Poster Bd #
H16
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Pharmacokinetic (PK) and exposure-response (ER) analysis of pertuzumab (P) in patients (pts) with HER2-positive metastatic gastroesophageal junction and gastric cancer (mGEJC/GC).
First Author: Whitney Paige Kirschbrown
Poster
2017 ASCO Annual Meeting
Is surgical resection beneficial in recurrent or metastatic gastric cancer?
First Author: Yong Won Choi
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world (RW) effectiveness of nivolumab plus chemotherapy (NIVO+chemo) in patients (pts) with advanced or metastatic gastric carcinoma, gastroesophageal junction carcinoma, or esophageal adenocarcinoma (GC/GEJC/EAC).
First Author: Ian Chau
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A randomized phase II/III study to evaluate the safety and efficacy of disitamab vedotin (DV) plus toripalimab and chemotherapy/trastuzumab as first-line treatment for HER2-expressed, locally advanced, or metastatic gastric cancer.
First Author: Lin Shen